PURPOSE AND METHODS: Studies on peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues have shown promising results with regard to tumour control. The efficacy of PRRT is limited by uptake and retention in the proximal tubules of the kidney, which might lead to radiation nephropathy. We investigated the long-term renal toxicity after different doses of [(177)Lu-DOTA(0),Tyr(3)]octreotate and the effects of dose fractionation and lysine co-injection in two tumour-bearing rat models. RESULTS: Significant renal toxicity was detected beyond 100 days after start of treatment as shown by elevated serum creatinine and proteinuria. Microscopically, tubules were strongly dilated with flat epithelium, containing protein cylinders. Creatinine levels rose significantly after 555 MBq [(177)Lu-DOTA(0),Tyr(3)]octreotate, but were significantly lower after 278 MBq (single injection) or two weekly doses of 278 MBq. Renal damage scores were maximal after 555 MBq and significantly lower in the 278 and 2x278 MBq groups. Three doses of 185 MBq [(177)Lu-DOTA(0),Tyr(3)]octreotate with intervals of a day, a week or a month significantly influenced serum creatinine (469+/-18, 134+/-70 and 65+/-15 micromol/l, respectively; p<0.001). Renal histological damage scores were not significantly influenced by dose fractionation. Lysine co-administration with three weekly treatments of 185 MBq significantly lowered serum creatinine and proteinuria. CONCLUSION: Injection of high doses of [(177)Lu-DOTA(0),Tyr(3)]octreotate resulted in severe renal damage in rats as indicated by proteinuria, elevated serum creatinine and histological damage. This damage was dose dependent and became overt between 100 and 200 days after treatment. Dose fractionation had significant beneficial effects on kidney function. Also, lysine co-injection successfully prevented functional damage.
PURPOSE AND METHODS: Studies on peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues have shown promising results with regard to tumour control. The efficacy of PRRT is limited by uptake and retention in the proximal tubules of the kidney, which might lead to radiation nephropathy. We investigated the long-term renal toxicity after different doses of [(177)Lu-DOTA(0),Tyr(3)]octreotate and the effects of dose fractionation and lysine co-injection in two tumour-bearing rat models. RESULTS: Significant renal toxicity was detected beyond 100 days after start of treatment as shown by elevated serum creatinine and proteinuria. Microscopically, tubules were strongly dilated with flat epithelium, containing protein cylinders. Creatinine levels rose significantly after 555 MBq [(177)Lu-DOTA(0),Tyr(3)]octreotate, but were significantly lower after 278 MBq (single injection) or two weekly doses of 278 MBq. Renal damage scores were maximal after 555 MBq and significantly lower in the 278 and 2x278 MBq groups. Three doses of 185 MBq [(177)Lu-DOTA(0),Tyr(3)]octreotate with intervals of a day, a week or a month significantly influenced serum creatinine (469+/-18, 134+/-70 and 65+/-15 micromol/l, respectively; p<0.001). Renal histological damage scores were not significantly influenced by dose fractionation. Lysine co-administration with three weekly treatments of 185 MBq significantly lowered serum creatinine and proteinuria. CONCLUSION: Injection of high doses of [(177)Lu-DOTA(0),Tyr(3)]octreotate resulted in severe renal damage in rats as indicated by proteinuria, elevated serum creatinine and histological damage. This damage was dose dependent and became overt between 100 and 200 days after treatment. Dose fractionation had significant beneficial effects on kidney function. Also, lysine co-injection successfully prevented functional damage.
Authors: J S Lewis; M Wang; R Laforest; F Wang; J L Erion; J E Bugaj; A Srinivasan; C J Anderson Journal: Int J Cancer Date: 2001-12-15 Impact factor: 7.396
Authors: B F Bernard; E Krenning; W A Breeman; T J Visser; W H Bakker; A Srinivasan; M de Jong Journal: Nucl Med Commun Date: 2000-11 Impact factor: 1.690
Authors: Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand Journal: J Nucl Med Date: 2002-05 Impact factor: 10.057
Authors: M de Jong; E J Rolleman; B F Bernard; T J Visser; W H Bakker; W A Breeman; E P Krenning Journal: J Nucl Med Date: 1996-08 Impact factor: 10.057
Authors: Astrid Capello; Eric Krenning; Bert Bernard; Jean-Claude Reubi; Wout Breeman; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2005-07-15 Impact factor: 9.236
Authors: Raffaella Barone; Stanislas Pauwels; Joëlle De Camps; Eric P Krenning; Larry K Kvols; M Charles Smith; Hakim Bouterfa; Olivier Devuyst; François Jamar Journal: Nephrol Dial Transplant Date: 2004-07-13 Impact factor: 5.992
Authors: Wouter A P Breeman; Amir Mearadji; Astrid Capello; Bert F Bernard; Casper H J van Eijck; Eric P Krenning; Marion de Jong Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: Edgar J Rolleman; Flavio Forrer; Bert Bernard; Magda Bijster; Marcel Vermeij; Roelf Valkema; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2006-12-05 Impact factor: 9.236
Authors: Sandra Heskamp; Reinier Hernandez; Janneke D M Molkenboer-Kuenen; Markus Essler; Frank Bruchertseifer; Alfred Morgenstern; Erik J Steenbergen; Weibo Cai; Christof Seidl; William J McBride; David M Goldenberg; Otto C Boerman Journal: J Nucl Med Date: 2017-02-23 Impact factor: 10.057
Authors: Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-14 Impact factor: 9.236
Authors: Erik Vegt; Annemarie Eek; Wim J G Oyen; Marion de Jong; Martin Gotthardt; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-01 Impact factor: 9.236